The country’s two biggest TAVR vendors both plan on making a splash at ACC.25. Medtronic and Edwards Lifesciences spoke to Cardiovascular Business about their plans for the three-day event in Chicago.

Laxmi Mehta, MD, explained that the use of statins when treating pregnant women is no longer forbidden. However, she added, cardiologists should always discuss it first with their patients.

Researchers focused on a relatively young patient population, hoping to learn as much as possible about the surgical valve's safety and effectiveness over an extended period of time. 

The subcutaneous drug, sold under the brand name Amvuttra, joins an ATTR-CM market that already includes Pfizer’s tafamidis (Vyndaqel, Vyndamax) and BridgeBio’s acoramidis (Attruby).

As coronary CT angiography (CCTA) continues its rapid expansion, scanner vendors are now offering more economical solutions to ensure access to imaging technology beyond premium systems most often only found at flagship hospitals and academic centers. To conquer CCTA’s technical challenges, new technologies and AI are being incorporated into a new scanner to simplify acquisition and consistently improve image quality. 

Steven Bolling, MD, noted that tricuspid treatments have been linked to consistent benefits in terms of quality of life. However, he said, finding clear improvements in clinical outcomes has been more challenging.

The drug in question, ataciguat, could help heart patients avoid aortic valve replacement—or at least put it off until later in life.

Abbott has received an investigational device exemption from the FDA for a new clinical trial evaluating the safety and effectiveness of using its coronary IVL technology. The trial is expected to enroll up to 335 U.S. patients.

Total artificial heart recipients typically stay in the hospital. In this case, however, the patient was able to wait for a donated heart from the comfort of his own home.

Multiple women have come forward with similar allegations against the Texas cardiologist. Police believe there may be additional victims as well.

Researchers explored data from nearly 80,000 patients, comparing the newest clot-busting stroke drug from Genetech with its predecessor.

Researchers have developed a new radiotracer that targets one of the virus’ spike proteins, allowing them to track it longitudinally.  

Duke University scientists are testing LLMs' ability to aid in this task—with the models able to recognize requests and generate responses.